Why We Entered the Field of Rare Disease Pharmaceuticals

An estimated 7,000 distinct rare diseases can be found around the world — many of them serious, progressive, and often life-threatening. Regrettably, there are still no effective therapeutic options for most of these diseases. To address this social problem, DyDo Pharma is committed to developing therapeutic medications for rare diseases whose symptoms often develop at birth or in early childhood, as well as for ultra-rare diseases with extremely few patients.

Our goal is to provide innovative medications in a timely manner to the patients who desperately need them by accelerating the development of new drug candidates licensed in from bio-ventures around the world in order to get marketing authorization approvals in Japan as quickly as possible.

We hope to gradually expand the therapeutic medications for various unexplored rare diseases, providing life-saving product to the patients who are combating those diseases and the medical practitioners who are striving to treat them. Through these efforts, we will ensure our commitment to building a happier and healthier society.

A leading player in the beverage market thanks to its popular canned coffee, DyDo Group is involved in a variety of other healthcare-related businesses including production of quasi-drug energy and beauty drinks, as well as sales of nutritionally functional foods and foods with functional claims (mail-order/online sales of supplements). Our recent entrance into the ethical drug field will further establish us as a major contributor to the healthcare field — a DyDo tradition we are proud to continue.